Financials
Financial year 2025
Pharmacycle from Brussel, company number BE0696815336, closed financial year 2025 with a result of € 5,640 after tax. For that financial year Pharmacycle recorded a gross margin of € 10,640 and equity of € 29,178. Compared with financial year 2024, the result moved from € 38,804 to € 5,640. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 29, 2026.
€ 29,178
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 5,640
▼ 85% vs 2024
Profit after tax over the fiscal year.
€ 2,731
▼ 77% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 5,640 paid out
100 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 4,868
▼ 37% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 928
▼ 62% vs 2024
Loans from banks and other lenders, long and short.
€ 303
▼ 60% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 5,143
▼ 41% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 15,006 | € 27,402 | € 55,865 | € 10,640 | ▼ 81% |
| Profit after taxes | € 7,831 | € 16,859 | € 38,804 | € 5,640 | ▼ 85% |
| Equity | € 34,187 | € 40,594 | € 29,178 | € 29,178 | |
| Total debts | € 4,247 | € 22,315 | € 62,214 | € 12,013 | ▼ 81% |
| Cash | € 24,632 | € 30,476 | € 12,014 | € 2,731 | ▼ 77% |
| Retained profit | € 32,187 | € 38,594 | € 27,178 | € 27,178 | |
| Dividend | € 800 | € 10,452 | € 50,220 | € 5,640 | ▼ 89% |
| Bank debt | € 1,535 | € 4,033 | € 2,458 | € 928 | ▼ 62% |
| Balance sheet total | € 38,435 | € 62,909 | € 91,392 | € 41,191 | ▼ 55% |
By gross margin, Pharmacycle ranks 44th of 50 companies with main activity “Detailhandel in farmaceutische producten” in Brussel that publish figures (fiscal year 2025).
Key figures of Pharmacycle, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about Pharmacycle the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Pharmacycle?
What happened at Pharmacycle in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 5,640 (▼ 85% vs 2024). Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Brussel. KBO
- Bjorn Steegen became a director. NBB
In short
From € 7,831 profit in 2022 to € 5,640 profit in 2025.
Paid € 26,644 in corporate taxes since 2022.
Best year ever: 2024, with € 38,804 profit.
Paid out € 67,113 in dividends to the owners in total.
Management
Behind Pharmacycle is Bjorn Steegen.
Directors
According to the 2025 annual accounts
Bjorn Steegen
Director
since 2018
Establishments
Establishment units
Physical locations of this company
Willebroekkaai 25 box 38
1000 Brussel
Stevinstraat 50
1000 Brussel
Active since 28 May 2018
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Brussel
Same main activity (Detailhandel in farmaceutische producten), 57 active companies in Brussel, largest first.
VERTEX PHARMACEUTICALS (BELGIUM)
€ 88.9 million revenue · 2025
€ 2.1 million gross margin · 2025
€ 1.5 million gross margin · 2025
€ 771,406 gross margin · 2025
€ 685,436 gross margin · 2025
€ 596,330 gross margin · 2024
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- STEEGEN Björn(enige deelgenoot) 100%
Details
- Company number
- 0696.815.336
- VAT number
- BE 0696.815.336
- Registered office
- Willebroekkaai 25 bus 38, 1000 Brussel
- Names & denominations
- Pharmacycle
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 May 2018
- Peppol
- Active · Active since 31 Oct 2023
- Contact
- [email protected]
- Activities · NACE
Detailhandel in farmaceutische producten
Organisatie van congressen en beurzen
Overige vormen van onderwijs
Beroepsopleiding
Overige zakelijke dienstverlening, neg